臨床外科72巻9号

2017年09月発行

特集 知っておきたい 乳がん診療のエッセンス

最近の話題

遺伝性乳がん

著者： 岩田広治¹ 吉村章代¹

所属機関： ¹愛知県がんセンター中央病院乳腺科

ページ範囲：P.1104 - P.1108

文献概要

【ポイント】
◆遺伝性乳がん卵巣がん症候群（HBOC）は常染色体優性遺伝であり，乳がん，卵巣がんなどを発症するリスクが高い．
◆HBOCに対するスクリーニング（一次拾い上げ）の意義は大きく，二次詳細評価のうえ可能性が高いと判断した人々には遺伝カウンセリングを提案する．
◆本稿ではHBOC乳がんに対する治療と予防的介入の現況について解説する．

参考文献

1）Melchor L, Benitez J：The complex genetic landscape of familial breast cancer. Hum Genet 132：845-863, 2013

2）Chen S, Parmigiani G：Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25：1329-1333, 2007

3）Sugano K, Nakamura S, Ando J, et al：Cross-sectional analysis of germline BRCA1 and BRCA2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer. Cancer Sci 99：1967-1976, 2008

4）National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment：Breast and Ovarian. ver 2. 2016

5）Pierce LJ, Phillips KA, Griffith KA, et al：Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer：comparison of breast conservation and mastectomy. Breast Cancer Res Treat 121：389-398, 2010

6）Templeton AJ, Gonzalez LD, Vera-Badillo FE, et al：Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations：a systematic review and meta-regression. PloS One 11：e0154789, 2016

7）Byrski T, Gronwald J, Huzarski T, et al：Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28：375-379, 2010

8）Vollebergh MA, Lips EH, Nederlof PM, et al：Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 16：R47, 2014

9）Ledermann J, Harter P, Gourley C, et al：Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer：a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15：852-861, 2014

10）Kaufman B, Shapira-Frommer R, Schmutzler RK, et al：Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33：244-250, 2015

11）Rebbeck TR, Friebel T, Lynch HT, et al：Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers：the PROSE Study Group. J Clin Oncol 22：1055-1062, 2004

12）Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al：Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer：a prospective analysis. Int J Cancer 136：668-677, 2015

13）Marchetti C, De Felice F, Palaia I, et al：Risk-reducing salpingo-oophorectomy：a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 14：150, 2014

14）King MC, Wieand S, Hale K, et al：Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2：National Surgical Adjuvant Breast and Bowel Project（NSABP-P1）Breast Cancer Prevention Trial. JAMA 286：2251-2256, 2001